Obesity and nonalcoholic fatty liver disease: current perspectives

References

• Onyekwere CA Ogbera AO Samaila AA Balogun BO Abdulkareem FB Nonalcoholic fatty liver disease: Synopsis of current developments Niger J Clin Pract 2015 18 6 703 712 26289505
   PubMed Web of Science ®Google Scholar
• Neuschwander-Tetri BA Non-alcoholic fatty liver disease BMC Med 2017 15 1 45 28241825
   PubMed Web of Science ®Google Scholar
• Chalasani N Younossi Z Lavine JE The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases Hepatology 2018 67 1 328 357 28714183
   PubMed Web of Science ®Google Scholar
• Kleiner DE Brunt EM van Natta M Design and validation of a histological scoring system for nonalcoholic fatty liver disease Hepatology 2005 41 6 1313 1321 15915461
   PubMed Web of Science ®Google Scholar
• Angulo P Kleiner DE Dam-Larsen S Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease Gastroenterology 2015 149 2 389 397 25935633
   PubMed Web of Science ®Google Scholar
• Ekstedt M Hagström H Nasr P Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up Hepatology 2015 61 5 1547 1554 25125077
   PubMed Web of Science ®Google Scholar
• Musso G Cassader M Rosina F Gambino R Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials Diabetologia 2012 55 4 885 904 22278337
   PubMed Web of Science ®Google Scholar
• Vilar-Gomez E Martinez-Perez Y Calzadilla-Bertot L Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis Gastroenterology 2015 149 2 367 378 25865049
   PubMed Web of Science ®Google Scholar
• Sofi F Macchi C Abbate R Gensini GF Casini A Mediterranean diet and health Biofactors 2013 39 4 335 342 23553669
   PubMed Web of Science ®Google Scholar
• Ryan MC Itsiopoulos C Thodis T The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease J Hepatol 2013 59 1 138 143 23485520
   PubMed Web of Science ®Google Scholar
• Kontogianni MD Tileli N Margariti A Adherence to the Mediterranean diet is associated with the severity of non-alcoholic fatty liver disease Clin Nutr 2014 33 4 678 683 24064253
   PubMed Web of Science ®Google Scholar
• Markova M Pivovarova O Hornemann S Isocaloric diets high in animal or plant protein reduce liver fat and inflammation in individuals with type 2 diabetes Gastroenterology 2017 152 3 571 585 27765690
   PubMed Web of Science ®Google Scholar
• St George A Bauman A Johnston A Farrell G Chey T George J Independent effects of physical activity in patients with nonalcoholic fatty liver disease Hepatology 2009 50 1 68 76 19444870
   PubMed Web of Science ®Google Scholar
• Sanyal AJ Chalasani N Kowdley KV Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis N Engl J Med 2010 362 18 1675 1685 20427778
   PubMed Web of Science ®Google Scholar
• Lavine JE Schwimmer JB van Natta ML Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial JAMA 2011 305 16 1659 1668 21521847
   PubMed Web of Science ®Google Scholar
• Miller ER3rd Pastor-Barriuso R Dalal D Riemersma RA Appel LJ Guallar E Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality Ann Intern Med 2005 142 1 37 46 15537682
   PubMed Web of Science ®Google Scholar
• Abner EL Schmitt FA Mendiondo MS Marcum JL Kryscio RJ Vitamin E and all-cause mortality: a meta-analysis Curr Aging Sci 2011 4 2 158 170 21235492
   PubMedGoogle Scholar
• Klein EA Thompson IM Tangen CM Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT) JAMA 2011 306 14 1549 1556 21990298
   PubMed Web of Science ®Google Scholar
• Musso G Cassader M Paschetta E Gambino R Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis JAMA Intern Med 2017 177 5 633 640 28241279
   PubMed Web of Science ®Google Scholar
• Yau H Rivera K Lomonaco R Cusi K The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus Curr Diab Rep 2013 13 3 329 341 23625197
   PubMed Web of Science ®Google Scholar
• Li Y Liu L Wang B Wang J Chen D Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis Biomed Rep 2013 1 1 57 64 24648894
   PubMedGoogle Scholar
• Musso G Gambino R Cassader M Pagano G A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease Hepatology 2010 52 1 79 104 20578268
   PubMed Web of Science ®Google Scholar
• Corey KE Misdraji J Gelrud L Zheng H Chung RT Krauss RM Nonalcoholic steatohepatitis is associated with an atherogenic lipopro-tein subfraction profile Lipids Health Dis 2014 13 1 100 24952382
   PubMed Web of Science ®Google Scholar
• Athyros VG Tziomalos K Gossios TD Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis Lancet 2010 376 9756 1916 1922 21109302
   PubMed Web of Science ®Google Scholar
• Tikkanen MJ Fayyad R Faergeman O Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels Int J Cardiol 2013 168 4 3846 3852 24001698
   PubMed Web of Science ®Google Scholar
• Lewis JH Mortensen ME Zweig S Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial Hepatology 2007 46 5 1453 1463 17668878
   PubMed Web of Science ®Google Scholar
• del Ben M Baratta F Polimeni L Under-prescription of statins in patients with non-alcoholic fatty liver disease Nutr Metab Cardiovasc Dis 2017 27 2 161 167 27914698
   PubMed Web of Science ®Google Scholar
• Konerman MA Jones JC Harrison SA Pharmacotherapy for NASH: Current and emerging J Hepatol 2018 68 2 362 375 29122694
   PubMed Web of Science ®Google Scholar
• Caldwell S Ikura Y Dias D Hepatocellular ballooning in NASH J Hepatol 2010 53 4 719 723 20624660
   PubMed Web of Science ®Google Scholar
• Pavlides M Banerjee R Tunnicliffe EM Multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity Liver Int 2017 37 7 1065 1073 27778429
   PubMed Web of Science ®Google Scholar
• Park CC Nguyen P Hernandez C Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease Gastroenterology 2017 152 3 598 607.e2 27911262
   PubMed Web of Science ®Google Scholar
• Sasso M Audière S Kemgang A Liver steatosis assessed by controlled attenuation parameter (CAP) measured with the XL probe of the FibroScan: a pilot study assessing diagnostic accuracy Ultrasound Med Biol 2016 42 1 92 103 26386476
   PubMed Web of Science ®Google Scholar
• Dulai PS Sirlin CB Loomba R MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice J Hepatol 2016 65 5 1006 1016 27312947
   PubMed Web of Science ®Google Scholar
• Golabi P Bush H Younossi ZM Treatment strategies for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis Clin Liver Dis 2017 21 4 739 753 28987260
   PubMed Web of Science ®Google Scholar
• Fuchs M Non-alcoholic fatty liver disease: the bile acid-activated farnesoid x receptor as an emerging treatment target J Lipids 2012 2012 1 8
   Google Scholar
• Ali AH Carey EJ Lindor KD Recent advances in the development of farnesoid X receptor agonists Ann Transl Med 2015 3 1 5 25705637
   PubMed Web of Science ®Google Scholar
• Neuschwander-Tetri BA Loomba R Sanyal AJ Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial Lancet 2015 385 9972 956 965 25468160
   PubMed Web of Science ®Google Scholar
• Gawrieh S Chalasani N Emerging treatments for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis Clin Liver Dis 2018 22 1 189 199 29128056
   PubMed Web of Science ®Google Scholar
• Ratziu V Sanyal AJ Macconell L Regenerate: a phase 3, double-blind, randomized, placebo-controlled multicenter study of obeticholic acid therapy for nonalcoholic steatohepatitis J Hepatol 2016 64 2 S294 S295
   Web of Science ®Google Scholar
• la Cour Poulsen L Siersbæk M Mandrup S PPARs: Fatty Acid Sensors Controlling Metabolism. Seminars in Cell & Developmental Biology Elsevier 2012 23 6 631 639 22273692
   PubMedGoogle Scholar
• Risérus U Sprecher D Johnson T Activation of peroxisome pro-liferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men Diabetes 2008 57 2 332 339 18024853
   PubMed Web of Science ®Google Scholar
• Ratziu V Harrison SA Francque S Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and-δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening Gastroen-terology 2016 150 5 1147 1159
   PubMed Web of Science ®Google Scholar
• Lefebvre E Moyle G Reshef R Antifibrotic effects of the dual CCR2/CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis PLoS One 2016 11 6 e0158156 27347680
   PubMed Web of Science ®Google Scholar
• Miura K Yang L van Rooijen N Ohnishi H Seki E Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2 Am J Physiol Gastrointest Liver Physiol 2012 302 11 G1310 G1321 22442158
   PubMed Web of Science ®Google Scholar
• Friedman SL Ratziu V Harrison SA A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis Hepatology 2018 67 5 1754 1767 28833331
   PubMed Web of Science ®Google Scholar
• Loomba R Lawitz E Mantry PS Jaya-kumar S Caldwell SH Arnold H GS-4997, An Inhibitor of Apoptosis Signal-Regulating Kinase (ASK1), Alone or in Combination With Simtuzumab for the Treatment of Nonalcoholic Steatohepatitis (NASH): A Randomized, Phase 2 Trial Hoboken (NJ) Wiley-Blackwell 2016
   Google Scholar
• ClinicalTrials.gov Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis (STELLAR3) Available from: https://clinicaltrials.gov/ct2/show/NCT03053050 Accessed August 3, 2018
   Google Scholar
• ClinicalTrials.gov Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (STELLAR 4) Available from: https://clinicaltrials.gov/ct2/show/NCT03053063 Accessed August 3, 2018
   Google Scholar
• Malhi H Camilleri M Modulating bile acid pathways and TGR5 receptors for treating liver and GI diseases Curr Opin Pharmacol 2017 37 80 86 29102744
   PubMed Web of Science ®Google Scholar
• Harrison SA Abdelmalek MF Trotter JF NGM282, a novel variant of FGF19, significantly reduces hepatic steatosis and key biomarkers of NASH: results of a phase 2, multicenter, randomized, double-blinded, placebo controlled trial in biopsy-confirmed NASH patients J Hepatol 2017 66 1 S92 S93
   Web of Science ®Google Scholar
• Sanyal A Charles ED Neuschwander-Tetri B BMS-986036 (pegylated FGF21) in patients with non-alcoholic steatohepatitis: a phase 2 study J Hepatol 2017 66 1 S89 S90
   Web of Science ®Google Scholar
• Marso SP Daniels GH Brown-Frandsen K Liraglutide and cardiovascular outcomes in type 2 diabetes N Engl J Med 2016 375 4 311 322 27295427
   PubMed Web of Science ®Google Scholar
• Armstrong MJ Gaunt P Aithal GP Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study Lancet 2016 387 10019 679 690 26608256
   PubMed Web of Science ®Google Scholar
• Sinha RA Singh BK Yen PM Direct effects of thyroid hormones on hepatic lipid metabolism Nat Rev Endocrinol 2018 14 5 259 269 29472712
   PubMed Web of Science ®Google Scholar
• Cable EE Finn PD Stebbins JW Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist Hepatology 2009 49 2 407 417 19072834
   PubMed Web of Science ®Google Scholar
• Harrison S GS2 MGL-3196, a selective thyroid hormone receptor-beta agonist significantly decreases hepatic fat in NASH patients at 12 weeks, the primary endpoint in a 36 week serial liver biopsy study Available from: http://www.madrigalpharma.com/wp-content/uploads/2018/01/Madrigal-Announces-EASL-Presentation.20180130_FINAL.pdf Accessed August 3, 2018
   Google Scholar
• Sosale A Saboo B Sosale B Saroglitazar for the treatment of hypertriglyceridemia in patients with type 2 diabetes: current evidence Diab Metab Syndrome Obes 2015 8 189 196
   PubMed Web of Science ®Google Scholar
• Colca JR Mcdonald WG Mccommis KS Finck BN Treating fatty liver disease by modulating mitochondrial pyruvate metabolism Hepatol Commun 2017 1 3 193 197 29404453
   PubMed Web of Science ®Google Scholar
• Fukunaga T Zou W Rohatgi N Colca JR Teitelbaum SL An insulin-sensitizing thiazolidinedione, which minimally activates PPARγ, does not cause bone loss J Bone Miner Res 2015 30 3 481 488 25257948
   PubMed Web of Science ®Google Scholar
• Wettstein G Luccarini J-M Poekes L Faye P Kupkowski F Adarbes V The new-generation pan-peroxisome proliferator-activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis Hepatol Commun [Internet] 2017 1 6 524 537 Available from: http://europepmc.org/abstract/MED/29404476 Accessed August 3, 2018.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov A Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-range, Proof-of-concept, 24-week Treatment Study of IVA337 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH) Available from: https://clinicaltrials.gov/ct2/show/NCT03008070 Accessed August 3, 2018
   Google Scholar
• Safadi R Konikoff FM Mahamid M The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease Clin Gastroenterol Hepatol 2014 12 12 2085 2091 24815326
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH (Aramchol_005) Available from: https://clinicaltrials.gov/ct2/show/NCT02279524 Accessed August 3, 2018
   Google Scholar
• ClinicalTrials.gov Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis (ENCORE-NF) Available from: https://clinicaltrials.gov/ct2/show/NCT02686762 Accessed August 3, 2018
   Google Scholar
• ClinicalTrials.gov Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis (ENCORE-LF) Available from: https://clinicaltrials.gov/ct2/show/NCT03205345 Accessed August 3, 2018
   Google Scholar
• Ir.conatuspharma.com Conatus Announces Exercise of License Option for Global Development and Commercialization of Emricasan Following Notice of Initiation of Phase 2b ENCORE-LF Clinical Trial in NASH Cirrhosis (NASDAQ:CNAT) Available from: http://ir.conatuspharma.com/releasedetail.cfm?releaseid=1024672 Accessed August 3, 2018
   Google Scholar